Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/5275
Title: Effects of short-term transdermal hormone replacement therapy on glycaemic control, lipid metabolism, C-reactive protein and proteinuria in postmenopausal women with type 2 diabetes or hypertension
Authors: Fenkçi, Semin
Fenkci, V.
Yilmazer, M.
Serteser, M.
Koken, T.
Keywords: CRP
Diabetes
HRT
Lipid-glucose metabolism
Proteinuria
amlodipine
antihypertensive agent
apolipoprotein A1
apolipoprotein B
C reactive protein
calcium channel blocking agent
cholesterol
creatinine
estracombi tts
estradiol plus norethisterone acetate
fructosamine
glucose
glycosylated hemoglobin
high density lipoprotein cholesterol
lipid
low density lipoprotein cholesterol
metformin
oral antidiabetic agent
protein
sex hormone
sulfonylurea derivative
triacylglycerol
very low density lipoprotein cholesterol
adult
article
blood pressure measurement
breast tenderness
cholesterol blood level
clinical article
controlled study
creatinine clearance
diastolic blood pressure
diet restriction
drug effect
female
glucose blood level
glucose metabolism
glucose tolerance
high risk patient
hormone substitution
human
hypertension
lipid blood level
lipid metabolism
menopausal syndrome
metrorrhagia
non insulin dependent diabetes mellitus
prospective study
protein urine level
proteinuria
short course therapy
statistical significance
systolic blood pressure
treatment outcome
treatment planning
triacylglycerol blood level
vagina bleeding
Publisher: Oxford University Press
Abstract: Background: The study was carried out to evaluate the effects of short-term transdermal hormone replacement therapy (HRT) on glycaemic control, lipid metabolism, C-reactive protein (CRP) and proteinuria in high-risk post-menopausal women. Methods: A total of 20 well-controlled type 2 diabetic, hypertensive and 21 well-controlled glucose-tolerant, hypertensive postmenopausal women were prospectively enrolled. After 12 weeks of transdermal HRT, the changes in serum lipid sub-fractions, fasting glucose, fructosamine, glycated haemoglobin (HbA1c), CRP, creatinine, 24 h urine protein levels, creatinine clearance and blood pressure were evaluated. Results: After 12 weeks of treatment, serum total-cholesterol and low-density cholesterols (LDL-cholesterol) appeared slightly reduced and serum triglyceride slightly elevated, although non-significantly so in both groups. The increase in HDL-cholesterol (P < 0.05) and reduction in very low density (VLDL)-cholesterol (P < 0.05) levels were significant in hypertensive patients. Elevation in the Apolipoprotein A1 (P < 0.05) and reduction in the Apolipoprotein B (P < 0.05) levels were statistically significant in all patients. HRT was associated with significant decreases in serum fasting glucose (P < 0.05) and fructosamine (P < 0.05) levels in diabetic patients. Serum HbA1c, CRP, creatinine, 24 h urine protein levels, creatinine clearance and systolic and diastolic blood pressure did not change significantly in either group. Conclusions: There were no detrimental effects of transdermal HRT on lipid profile, glucose metabolism, CRP and urine protein levels in our well-controlled diabetic or hypertensive patients. A decision regarding HRT use should be taken on a case-by-case basis.
Results:All of the patients completed the study. The mean body mass index (BMI) was 31.27 and 30.95 kg/m2 in the DM-HRT and HT-HRT groups respectively. Estraderm TTS plus NETA was associated with statistically significant decreases in serum mean fasting glucose and fructosamine levels, and with a non-significant reduction in serum mean HbA1c level in the DM-HRT group. Significant changes were seen in mean serum VLDL (decreased) and HDL-cholesterol (increased) levels in the HT-HRT group. The increase in mean serum Apo-A1 level and the reduction in mean serum Apo-B level were statistically significant in both treatment groups. Serum CRP, creatinine, 24 h urine protein levels, creatinine clearance and systolic and diastolic blood pressure did not change significantly during 12 weeks of transdermal HRT in both groups. High-risk postmenopausal women did not have any adverse effect on proteinuria and serum creatinine levels after 3 months of Estraderm TTS plus NETA treatment.
TypeofStudy:A prospective, open study evaluating the effects of short-term hormone replacement therapy (HRT) Estraderm TTS plus norethisterone acetate (NETA) (=Estracombi TTS) on glycemic control, lipid metabolism, C-reactive protein (CRP) and proteinuria in high-risk postmenopausal women with diabetes and/or hypertension.
DosageDuration:17beta-estradiol 0.05 mg daily and sequential norethisterone acetate 0.25 mg daily transdermally. Duration was 12 weeks.
AdverseEffects:2 subjects (10%) in the DM-HRT group and 1 subject (4.7%) in the HT-HRT group complained about abnormal vaginal bleeding such as metrorrhagia and 4 patients (19%) reported breast tenderness in the HT-HRT group. No patient experienced detrimental effects on lipid profile, glucose metabolism, CRP and urine protein levels.
AuthorsConclusions:Additional research will be necessary to determine the effects of long-term transdermal HRT in high-risk postmenopausal women. We conclude that decisions about HRT should be taken on a case-by-case basis, and in doing so it is important to include the potential personal benefits and risk profile, especially in high-risk postmenopausal women.
FreeText:In order to maintain their glucose levels in an acceptable range, women with type 2 diabetes were on dietary management alone (2 patients) or taking oral antidiabetic drugs that consisted of metformin and sulfonylureas (18 patients). Each diabetic patient received a diabetic diet with <30% of total calories as fat, ?10% saturated fat, ?10% monounsaturated fat and ?10% polyunsaturated fat. All patients took amlodipine 5-10 mg daily as an antihypertensive drug. The antidiabetic and antihypertensive medications were left unchanged during the study. Metabolic and physical examinations were performed at the onset of the study and then again after 12 weeks of receiving HRT. Blood pressure was measured during two clinical evaluations by an average of three measurements taken in the sitting position before the morning dose of the antihypertensive therapy. On the fourth day of the third hormonal cycle (in the estrogen only phase), blood samples were taken after a 10 h fast and serum total cholesterol (total cholesterol), triglyceride (TG), high density cholesterol (HDL-cholesterol), VLDL-cholesterol, apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), serum creatinine (sCr), urine creatinine (uCr), 24 h urine protein, fructosamine, HbA1c and glucose levels were determined in an automated analyzer. Low-density cholesterol (LDL cholesterol) levels were calculated by using Friedewald's formula. Serum CRP was turbidimetrically determined by clinical chemistry system.
Indications:20 patients with diabetes type 2 and hypertension and 21 patients with hypertension.
Patients:41 postmenopausal women. Type 2 diabetes and hypertension group (DM-HRT group): n=20, mean age was 50.9 years. Hypertension group (HT-HRT group): n=21, mean age was 52.6 years.
URI: https://hdl.handle.net/11499/5275
https://doi.org/10.1093/humrep/deg146
ISSN: 0268-1161
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
deg146.pdf93.39 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

22
checked on Sep 30, 2024

WEB OF SCIENCETM
Citations

19
checked on Sep 30, 2024

Page view(s)

46
checked on Aug 24, 2024

Download(s)

22
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.